3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents

Michael Maeng; Hans-Henrik Tilsted; Lisette Okkels Jensen; Anne Kjer Kaltoft; Henning Kelbæk; Ulrik Abildgaard; Anton B Villadsen; Lars Romer Krusell; Jan Ravkilde; Knud Nørregaard Hansen; Evald Høj Christiansen; Jens Aarøe; Jan Skov Jensen; Steen Dalby Kristensen; Hans Erik Bøtker; Morten Madsen; Per Thayssen; Henrik Toft Sørensen; Leif Thuesen; Jens Flensted Lassen

doi:10.1016/j.jcin.2012.04.008

3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents

Michael Maeng, Hans-Henrik Tilsted, Lisette Okkels Jensen, Anne Kjer Kaltoft, Henning Kelbæk, Ulrik Abildgaard, Anton B Villadsen, Lars Romer Krusell, Jan Ravkilde, Knud Nørregaard Hansen, Evald Høj Christiansen, Jens Aarøe, Jan Skov Jensen, Steen Dalby Kristensen, Hans Erik Bøtker, Morten Madsen, Per Thayssen, Henrik Toft Sørensen, Leif Thuesen, Jens Flensted Lassen

38 Citationer (Scopus)

Abstract

This study sought to examine the 3-year clinical outcomes in patients treated with the Endeavor (Medtronic, Santa Rosa, California) zotarolimus-eluting stent (ZES) or the Cypher (Cordis, Johnson & Johnson, Warren, New Jersey) sirolimus-eluting stent (SES) in routine clinical practice.

Originalsprog	Engelsk
Tidsskrift	Circulation. Cardiovascular interventions
Vol/bind	5
Udgave nummer	8
Sider (fra-til)	812-8
Antal sider	7
ISSN	1941-7640
DOI	https://doi.org/10.1016/j.jcin.2012.04.008
Status	Udgivet - 2012

Adgang til dokumentet

10.1016/j.jcin.2012.04.008

Citationsformater

Maeng, M., Tilsted, H.-H., Jensen, L. O., Kaltoft, A. K., Kelbæk, H., Abildgaard, U., Villadsen, A. B., Krusell, L. R., Ravkilde, J., Hansen, K. N., Christiansen, E. H., Aarøe, J., Jensen, J. S., Kristensen, S. D., Bøtker, H. E., Madsen, M., Thayssen, P., Sørensen, H. T., Thuesen, L., & Lassen, J. F. (2012). 3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents. Circulation. Cardiovascular interventions, 5(8), 812-8. https://doi.org/10.1016/j.jcin.2012.04.008

Maeng, M, Tilsted, H-H, Jensen, LO, Kaltoft, AK, Kelbæk, H, Abildgaard, U, Villadsen, AB, Krusell, LR, Ravkilde, J, Hansen, KN, Christiansen, EH, Aarøe, J, Jensen, JS, Kristensen, SD, Bøtker, HE, Madsen, M, Thayssen, P, Sørensen, HT, Thuesen, L & Lassen, JF 2012, '3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents', Circulation. Cardiovascular interventions, bind 5, nr. 8, s. 812-8. https://doi.org/10.1016/j.jcin.2012.04.008

@article{d975890222274568b0887bb3f240b4e2,

title = "3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents",

abstract = "This study sought to examine the 3-year clinical outcomes in patients treated with the Endeavor (Medtronic, Santa Rosa, California) zotarolimus-eluting stent (ZES) or the Cypher (Cordis, Johnson & Johnson, Warren, New Jersey) sirolimus-eluting stent (SES) in routine clinical practice.",

author = "Michael Maeng and Hans-Henrik Tilsted and Jensen, {Lisette Okkels} and Kaltoft, {Anne Kjer} and Henning Kelb{\ae}k and Ulrik Abildgaard and Villadsen, {Anton B} and Krusell, {Lars Romer} and Jan Ravkilde and Hansen, {Knud N{\o}rregaard} and Christiansen, {Evald H{\o}j} and Jens Aar{\o}e and Jensen, {Jan Skov} and Kristensen, {Steen Dalby} and B{\o}tker, {Hans Erik} and Morten Madsen and Per Thayssen and S{\o}rensen, {Henrik Toft} and Leif Thuesen and Lassen, {Jens Flensted}",

year = "2012",

doi = "10.1016/j.jcin.2012.04.008",

language = "English",

volume = "5",

pages = "812--8",

journal = "Circulation. Cardiovascular interventions",

issn = "1941-7640",

publisher = "Lippincott Williams and Wilkins",

number = "8",

}

TY - JOUR

T1 - 3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents

AU - Maeng, Michael

AU - Tilsted, Hans-Henrik

AU - Jensen, Lisette Okkels

AU - Kaltoft, Anne Kjer

AU - Kelbæk, Henning

AU - Abildgaard, Ulrik

AU - Villadsen, Anton B

AU - Krusell, Lars Romer

AU - Ravkilde, Jan

AU - Hansen, Knud Nørregaard

AU - Christiansen, Evald Høj

AU - Aarøe, Jens

AU - Jensen, Jan Skov

AU - Kristensen, Steen Dalby

AU - Bøtker, Hans Erik

AU - Madsen, Morten

AU - Thayssen, Per

AU - Sørensen, Henrik Toft

AU - Thuesen, Leif

AU - Lassen, Jens Flensted

PY - 2012

Y1 - 2012

N2 - This study sought to examine the 3-year clinical outcomes in patients treated with the Endeavor (Medtronic, Santa Rosa, California) zotarolimus-eluting stent (ZES) or the Cypher (Cordis, Johnson & Johnson, Warren, New Jersey) sirolimus-eluting stent (SES) in routine clinical practice.

AB - This study sought to examine the 3-year clinical outcomes in patients treated with the Endeavor (Medtronic, Santa Rosa, California) zotarolimus-eluting stent (ZES) or the Cypher (Cordis, Johnson & Johnson, Warren, New Jersey) sirolimus-eluting stent (SES) in routine clinical practice.

U2 - 10.1016/j.jcin.2012.04.008

DO - 10.1016/j.jcin.2012.04.008

M3 - Journal article

C2 - 22917452

SN - 1941-7640

VL - 5

SP - 812

EP - 818

JO - Circulation. Cardiovascular interventions

JF - Circulation. Cardiovascular interventions

IS - 8

ER -

3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater